While TAF is still in Phase III clinical trials, early data suggests it could be a key ingredient in the next generation of first-line fixed-dose treatment options for children living with HIV.
"With only one in four children living with HIV currently getting treatment, we cannot continue to do business as usual," said Charles Lyons, EGPAF president and CEO. "We congratulate MPP and Gilead on this expanded collaboration and their proactive efforts to support countries and populations hardest hit by HIV and AIDS. This is the kind of innovative action that we need now to protect the health of affected children and in order to achieve an AIDS-free generation."
The license will allow manufacturers in India and China to develop generic versions of TAF for 112 countries that are home to more than 92 percent of people living with HIV in the developing world.
Every day, almost 700 babies are newly infected with HIV, almost all of whom live in sub-Saharan Africa. EGPAF and its affiliates have provided critical HIV care and treatment to more than 2 million individuals, including 160,000 children and enrolled more than 95,000 children on antiretroviral therapy.
About the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF):
EGPAF is the global leader in the fight against pediatric HIV/ AIDS and has reached 20 million women with services to prevent transmission of HIV to their babies. It currently supports more than 7,000 health facilities and works in 15 countries to implement prevention, care, and treatment services; to further advance innovative research; and to execute global advocacy activities that bring dramatic change to the lives of millions of women, children, and families worldwide. For more information, visit www.pedaids.org.